GSK plc announced that the European Medicines Agency accepted the marketing application for Blenrep on July 19, 2024, which aims to improve treatment outcomes for multiple myeloma. The application is supported by positive results from Phase III trials showing significant benefits in progression-free survival compared to standard therapies.